QuestionSBA
QuestionChoice
Dyspepsia is not a known adverse effect associated with warfarin
34321
b
Patient reports new dyspepsia
QuestionChoice
Vitamin K assays are not routinely done in patients taking warfarin as levels will almost certainly be lower and as such this is of negligible clinical usefulness
34324
e
Vitamin K levels
QuestionChoice
The prothrombin time has no role in monitoring either the dosing or adverse effects of warfarin
34323
d
Prothrombin time
QuestionChoice
Warfarin has no effect on platelets and thus they have no role in monitoring either the dosing or adverse effects of warfarin
34322
c
Platelet count
QuestionChoice
When starting anticoagulation treatment it is important for patients to report any new bruising or bleeding as they may be receiving too high a dose
34320
a
Patient reports easy bruising
QuestionComment
WTF

37592
User
subscriber
Intravenous Ketone
QuestionComment
Surely not
40474
User
subscriber
Embolism Cystic
QuestionComment
lol its PROthrombin time not TT rip my sanity
61792
User
subscriber
Pseudopseudopseudopseudohypoparathyroidism
Concept
Chapter
#### Monitoring

The BNF advises to monitor lung function (in patients with a history of obstructive airway disease).

#### Overdoses

Overdosages with beta-blockers may cause cardiac effects such as bradycardia, hypotension, syncope, conduction abnormalities, and heart failure. Bradycardia is the most common arrhythmia, but some beta-blockers may induce ventricular tachyarrhythmias secondary to prolongation of QT interval (e.g. sotalol) or QRS duration (e.g. propranolol).
Non-cardiovascular effects include central nervous system effects (including drowsiness, confusion, convulsions, hallucinations, and in severe cases coma), respiratory depression, and bronchospasm.

Management
 - Airway protection 
 - Activated charcoal within 1 hour
 - IV Fluids
 
IV glucagon is the first-line management.
 
For symptomatic bradycardia, IV atropine may be used.

2618
2807
Warfarin side effects
Topic
9
Internal Medicine
6875
Case Presentation: A 37 year old woman is referred to the anticoagulation clinic following a hospital admission for a pulmonary embolus. **PMH** systemic lupus erythematosus, antiphospholipid syndrome. **DH** hydroxychloroquine sulfate 300mg PO OD. NKDA **SH** ex-smoker (5 pack years).


Her consultant decides that it is appropriate to pursue lifelong anticoagulation with warfarin sodium at a starting dose of 5mg PO OD.

Question: Select the most appropriate option to monitor for adverse effects of this treatment in the first few months.
a